- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
CTD Holdings Enrolls First Patient in Phase I Clinical Trial
CTD Holdings announced it enrolled the first patient in their phase 1 clinical trial evaluating the intravenous administration of Trappsol Cyclo in patients with Niemann-Pick Disease Type C.
CTD Holdings (OTCQB:CTDH) announced it enrolled the first patient in their phase 1 clinical trial evaluating the intravenous administration of Trappsol Cyclo in patients with Niemann-Pick Disease Type C.
As quoted in the press release:
NPC is a rare and fatal genetic disease that impacts the brain, lung, liver, spleen, and other organs. The first patient was enrolled at UCSF Benioff Children’s Hospital Oakland, the single site for this trial, by Dr. Caroline Hastings, pediatric hematologist and oncologist. Dr. Hastings is the Principal Investigator for the US Phase I trial.
The Phase I clinical trial will require 12 patients to be fully enrolled. It is a double-blind randomized trial evaluating two doses of Trappsol® Cyclo™, 1500 mg/kg or 2500 mg/kg, in NPC patients 18 years of age and older. Trappsol® Cyclo™ will be administered intravenously via bi-monthly injections over a period of 14 weeks.
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.